Home » Stocks » ARDS

Aridis Pharmaceuticals Inc. (ARDS)

Stock Price: $6.35 USD 0.10 (1.60%)
Updated May 12, 2021 3:39 PM EDT - Market closed
Market Cap 67.51M
Revenue (ttm) 1,000,000
Net Income (ttm) -23.71M
Shares Out 11.23M
EPS (ttm) -2.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $6.35
Previous Close $6.25
Change ($) 0.10
Change (%) 1.60%
Day's Open 6.10
Day's Range 6.01 - 6.40
Day's Volume 3,932
52-Week Range 4.70 - 9.97

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LOS GATOS, Calif., May 11, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...

1 day ago - PRNewsWire

PARAMUS, N.J.--(BUSINESS WIRE)--Kermode Biotechnologies, Inc., announced that it is actively engaged in discovery to identify the mode of transmission and replication for the ASFV.

2 weeks ago - Business Wire

PARAMUS, N.J.--(BUSINESS WIRE)--Kermode Biotechnologies, Inc., announced that it is actively engaged in discovery to identify the mode of transmission and replication for the ASFV.

2 weeks ago - Business Wire

LOS GATOS, Calif., March 30, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to t...

1 month ago - PRNewsWire

LOS GATOS, Calif., March 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to t...

1 month ago - PRNewsWire

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has entered into an out-licensing and product discovery agreement with a privately-held Kermode Biotechnologies Inc. Kermode works on vaccines and mAbs for zoon...

2 months ago - Benzinga

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has added its inhaled AR-711 monoclonal antibody with a second antibody, AR-713, designed to neutralize newly emerging COVID-19 mutated variants. The company sa...

2 months ago - Benzinga

LOS GATOS, Calif., Feb. 23, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tr...

2 months ago - PRNewsWire

SAN JOSE, Calif., Nov. 24, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...

5 months ago - PRNewsWire

SAN JOSE, Calif., Nov. 20, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...

5 months ago - PRNewsWire

SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...

6 months ago - PRNewsWire

SAN JOSE, Calif., Oct. 19, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...

6 months ago - PRNewsWire

SAN JOSE, Calif., Oct. 14, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company"), a biopharmaceutical company focused on the discovery and development of novel anti-infective ...

6 months ago - PRNewsWire

SAN JOSE, Calif., Sept. 8, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc.

8 months ago - PRNewsWire

SAN JOSE, Calif., Sept. 4, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc.

8 months ago - PRNewsWire

SAN JOSE, Calif., Aug. 11, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc.

9 months ago - PRNewsWire

SAN JOSE, Calif., June 26, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...

10 months ago - PRNewsWire

The SPDR S&P 500 (NYSE: SPY) started off the week on a high note on Monday morning after a turbulent week of trading last week.

Other stocks mentioned: CGC, DB, DRI, HSBC, KPTI, NKE, UBS ...
10 months ago - Benzinga

SAN JOSE, Calif., June 22, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...

10 months ago - PRNewsWire

SAN JOSE, Calif., June 15, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to tre...

10 months ago - PRNewsWire

As of late, it has definitely been a great time to be an investor Aridis Pharmaceuticals

1 year ago - Zacks Investment Research

Shares of the thinly traded, micro-cap biotech Aridis Pharmaceuticals Inc (NASDAQ: ARDS) were retreating to a one-week low Tuesday morning.

1 year ago - Benzinga

Shares of Aridis Pharmaceuticals Inc. plunged 27% to pace all premarket decliners Tuesday, after the biopharmaceutical company said a phase 2 trial of its treatment of ventilator-associated pneumonia (A...

1 year ago - Market Watch

Aridis Pharmaceuticals has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 years ago - Zacks Investment Research

About ARDS

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginos... [Read more...]

Industry
Biotechnology
IPO Date
Aug 10, 2018
Stock Exchange
NASDAQ
Ticker Symbol
ARDS
Full Company Profile

Financial Performance

In 2020, ARDS's revenue was $1,000,000, a decrease of -2.15% compared to the previous year's $1.02 million. Losses were -$22.33 million, -24.76% less than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for ARDS stock is "Buy." The 12-month stock price forecast is 17.00, which is an increase of 167.72% from the latest price.

Price Target
$17.00
(167.72% upside)
Analyst Consensus: Buy